Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Angiogenesis in lymphoproliferative disorders.

P Salven1

  • 1Division of Hematology-Oncology, Weill Medical College of Cornell University, New York, NY 10021, USA. pjs2004@med.cornell.edu

Acta Haematologica
|January 30, 2002
PubMed
Summary

Angiogenesis is crucial in blood cancers like leukemia and lymphoma. Targeting blood vessel growth with antiangiogenic drugs offers a promising new treatment strategy for these lymphoproliferative disorders.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Endotoxins induce and interferon alpha suppresses vascular endothelial growth factor (VEGF) production in human peripheral blood mononuclear cells.

FASEB journal : official publication of the Federation of American Societies for Experimental Biology·2001
Same author

Interferon alpha-2a therapy in 18 hemangioblastomas.

Clinical cancer research : an official journal of the American Association for Cancer Research·2001
Same author

Simultaneous elevation in the serum concentrations of the angiogenic growth factors VEGF and bFGF is an independent predictor of poor prognosis in non-Hodgkin lymphoma: a single-institution study of 200 patients.

Blood·2000
Same author

Major surgery increases serum levels of vascular endothelial growth factor only temporarily.

American journal of surgery·2000
Same author

A high pretreatment serum basic fibroblast growth factor concentration is an independent predictor of poor prognosis in non-Hodgkin's lymphoma.

Blood·1999
Same author

Kaposi's sarcoma-associated herpesvirus-encoded v-cyclin triggers apoptosis in cells with high levels of cyclin-dependent kinase 6.

Cancer research·1999

Area of Science:

  • Hematology
  • Oncology
  • Molecular Biology

Background:

  • Angiogenesis, or new blood vessel formation, is vital in solid tumors.
  • Recent research highlights angiogenesis's significance in hematological malignancies, including leukemia, lymphoma, and multiple myeloma.
  • Understanding these mechanisms is key for developing novel therapies.

Purpose of the Study:

  • To review the cellular and molecular mechanisms of angiogenesis in lymphoproliferative disorders.
  • To explore potential therapeutic applications targeting angiogenesis in these conditions.

Main Methods:

  • Literature review of studies on angiogenesis in hematological malignancies.
  • Analysis of the role of angiogenic factors like vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF).

Main Results:

  • Expression of VEGF and bFGF correlates with clinical features in leukemia and lymphoma.
  • Serum concentrations of these factors predict a poor prognosis.
  • Angiogenesis plays a critical role in the progression of lymphoproliferative disorders.

Conclusions:

  • Antiangiogenic therapies, including drugs like thalidomide and VEGF receptor inhibitors, show promise.
  • These agents can be used alone or with standard treatments for lymphoproliferative disorders.
  • Targeting angiogenesis represents a significant therapeutic avenue for hematological malignancies.

Related Experiment Videos